Alliance for Pandemic Preparedness

February 24, 2021

SARS-CoV-2 B.1.1.7 Sensitivity to MRNA Vaccine-Elicited, Convalescent and Monoclonal Antibodies

Category:

Topic:

Keywords (Tags): ,

[Pre-print, not peer-reviewed] An assessment of immune responses following a single dose of the Pfizer-BioNTech vaccine (BNT162b2) vaccine using pseudoviruses expressing the wild-type Spike protein or the B.1.1.7 spike protein showed that the vaccine-elicited antibodies modestly reduced activity against the B.1.1.7 variant. This reduction was also observed in sera from some convalescent patients and with monoclonal antibodies (mAbs) targeting the N-terminal domain (9 out of 10) and the Receptor Binding Motif (RBM) (5 out of 31), but not in neutralizing mAbs binding outside the RBM. Introduction of the E484K mutation in B.1.1.7 led to a greater loss of neutralizing activity by sera from vaccinees and mAbs (19 out of 31). 

Collier et al. (Feb 2021). SARS-CoV-2 B.1.1.7 Sensitivity to MRNA Vaccine-Elicited, Convalescent and Monoclonal Antibodies. Pre-print downloaded Feb 24 from https://doi.org/10.1101/2021.01.19.21249840